Last reviewed · How we verify
Placebo of CM326
Placebo of CM326 is a Small molecule drug developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control arm and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of CM326 |
|---|---|
| Sponsor | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is pharmacologically inert and serves as a control comparator in clinical trials. It is used to establish the baseline efficacy and safety profile of the active investigational drug CM326 through blinded comparison.
Approved indications
Common side effects
Key clinical trials
- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis (PHASE3)
- A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma (PHASE3)
- Study of CM326 Injection in Healthy Subjects (PHASE1)
- A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps (PHASE1, PHASE2)
- Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis (PHASE2)
- A Study of CM326 in Subjects With Moderate to Severe Asthma (PHASE2)
- A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of CM326 CI brief — competitive landscape report
- Placebo of CM326 updates RSS · CI watch RSS
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. portfolio CI